PMID- 17541725
OWN - NLM
STAT- MEDLINE
DCOM- 20080410
LR  - 20181113
IS  - 1569-5794 (Print)
IS  - 1569-5794 (Linking)
VI  - 24
IP  - 2
DP  - 2008 Feb
TI  - Angiographic and 3D intravascular ultrasound assessment of overlapping bare metal 
      stent and three different formulations of drug-eluting stents in patients with 
      diabetes mellitus.
PG  - 125-32
AB  - OBJECTIVES: The aim of this study was to examine the impact of overlapping 
      bare-metal stent (BMS) and three different formulations of drug-eluting stent 
      (DES) on intimal hyperplasia (IH) response of patients with diabetes mellitus 
      (DM). METHODS: Forty-nine DM patients treated with overlapping BMS (19 lesions), 
      sirolimus-eluting stent (SES 12 lesions), paclitaxel-eluting stent (PES 8 
      lesions) or tacrolimus-eluting stent (TES 10 lesions) were studied. Baseline and 
      9-month follow-up volumetric intravascular vascular ultrasound (IVUS) and 
      quantitative coronary angiography (QCA) analysis were performed in the entire 
      stented segment and in the overlapped (OL) and non-overlapped (non-OL) 
      subsegments. Clinical outcomes were evaluated at 1-year follow-up. RESULTS: 
      Post-procedure (PO-) QCA measurements were similar in all stent groups, and 
      between OL and non-OL subsegments in each individual type of stents. Percent IH 
      was lower in SES and PES vs. BMS (p < 0.05). Percent IH was significantly greater 
      in OL subsegment compared with non-OL subsegment in BMS (p < 0.05), but not in 
      all type of DES groups. SES showed significantly less %IH compared with PES and 
      TES in OL and non-OL subsegments. Vessel area at the OL remained unchanged from 
      PO to FU in all type of DES and BMS groups. There were no aneurysm formation and 
      no stent thrombosis up to 1-year follow-up. CONCLUSIONS: Overlapping BMS is 
      associated with enhanced IH response in diabetic patients, whereas overlapping 
      DES, particularly SES and PES, appear effective to inhibit IH without detectable 
      late vascular adverse effects.
FAU - Kawaguchi, Ren
AU  - Kawaguchi R
AD  - Division of Cardiology and Cardiovascular Imaging Core Laboratories, University 
      of Florida Shands Jacksonville, Jacksonville, FL 32209, USA.
FAU - Sabate, Manel
AU  - Sabate M
FAU - Angiolillo, Dominick J
AU  - Angiolillo DJ
FAU - Jimenez-Quevedo, Pilar
AU  - Jimenez-Quevedo P
FAU - Suzuki, Nobuaki
AU  - Suzuki N
FAU - Corros, Cecilia
AU  - Corros C
FAU - Futamatsu, Hideki
AU  - Futamatsu H
FAU - Alfonso, Fernando
AU  - Alfonso F
FAU - Hernandez-Antolin, Rosana
AU  - Hernandez-Antolin R
FAU - Macaya, Carlos
AU  - Macaya C
FAU - Bass, Theodore A
AU  - Bass TA
FAU - Costa, Marco A
AU  - Costa MA
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
DEP - 20070531
PL  - United States
TA  - Int J Cardiovasc Imaging
JT  - The international journal of cardiovascular imaging
JID - 100969716
RN  - P88XT4IS4D (Paclitaxel)
RN  - W36ZG6FT64 (Sirolimus)
RN  - WM0HAQ4WNM (Tacrolimus)
SB  - IM
MH  - Analysis of Variance
MH  - *Coronary Angiography
MH  - Coronary Disease/diagnostic imaging/*therapy
MH  - Diabetes Complications/diagnostic imaging/*therapy
MH  - *Drug-Eluting Stents
MH  - Female
MH  - Humans
MH  - Hyperplasia/prevention & control
MH  - *Imaging, Three-Dimensional
MH  - Male
MH  - Paclitaxel/administration & dosage
MH  - Prospective Studies
MH  - Sirolimus/administration & dosage
MH  - *Stents
MH  - Tacrolimus/administration & dosage
MH  - Treatment Outcome
MH  - Tunica Intima/diagnostic imaging/*drug effects
MH  - *Ultrasonography, Interventional
EDAT- 2007/06/02 09:00
MHDA- 2008/04/11 09:00
CRDT- 2007/06/02 09:00
PHST- 2007/02/01 00:00 [received]
PHST- 2007/05/04 00:00 [accepted]
PHST- 2007/06/02 09:00 [pubmed]
PHST- 2008/04/11 09:00 [medline]
PHST- 2007/06/02 09:00 [entrez]
AID - 10.1007/s10554-007-9235-7 [doi]
PST - ppublish
SO  - Int J Cardiovasc Imaging. 2008 Feb;24(2):125-32. doi: 10.1007/s10554-007-9235-7. 
      Epub 2007 May 31.